Evening the score on sex drugs: Feminist movement or marketing masquerade?

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Moynihan, Ray ^a  

^a BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLIBANSERIN; SILDENAFIL; ANTIDEPRESSANT AGENT; BENZIMIDAZOLE DERIVATIVE;

DIZZINESS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TREATMENT FAILURE; DSM-5; FATIGUE; FEMINISM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; NAUSEA; SCORING SYSTEM; SHORT SURVEY; SOMNOLENCE; UNITED STATES; DRUG APPROVAL; FEMALE; FINANCIAL MANAGEMENT; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

ANTIDEPRESSIVE AGENTS; BENZIMIDAZOLES; DRUG APPROVAL; FEMALE; FEMINISM; HUMANS; MARKETING OF HEALTH SERVICES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84908136155     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g6246     Document Type: Short Survey

References (12)

1. DeBruyn J. Raleigh company hauls $15m war chest to develop "female Viagra." Triangle Business Journal 2014 Aug 21, www.bizjournals.com/triangle/news/2014/08/21/sproutraises-15m-to-develop-flibanserin-raleigh.html?page=all.
2. Moynihan R. Merging of marketing and medical science: female sexual dysfunction. BMJ 2010;341:c5050.
3. Moynihan R. Drug for low sexual desire carries significant harms, FDA advisers find. BMJ 2010;341:c3339.
4. Sprout Pharmaceuticals. Sprout Pharmaceuticals appeals FDA decision on new drug application for flibanserin to treat hypoactive sexual desire disorder in premenopausal women. Press release, 11 December 2013. http://sproutpharma.com/sprout-pharmaceuticals-appeals-fda-decision-on-new-drug-application-for-flibanserin-to-treathypoactive-sexual-desire-disorder-in-premenopausal-women/.
5. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013;10:1807-15.
6. Lexchin J, Bero L, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 2003;326:1167.
7. Moynihan R, Mintzes B. Sex lies and pharmaceuticals. Greystone, 2010.
8. American Psychiatric Association. Highlights of changes from DSM-IV-TR to DSM-5. 2013. www.dsm5.org/Documents/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf.
9. American Sexual Health Association. Form 990. Return of organization exempt from income tax, for 7/01/12 to 6/30/13. www.ashasexualhealth.org/pdfs/990-FY13.pdf.
10. Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes,RA, Vogel Marler S, et al. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin - norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes 2014;7:459.
11. Moynihan R. The marketing of a disease: female sexual dysfunction. BMJ 2005;330:192.
12. FDA. Warning letter to Slate Pharmaceuticals 3/24/10. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm259232.htm.